Novavax
Business Services · Maryland, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
21 Firstfield Rd, Gaithersburg, Maryland...Phone Number
(844) 668-2829Website
www.novavax.comRevenue
$413.8 MillionStock Symbol
NVAXIndustry
ZI Rank: 2
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
5
1
2
2
2
2
About Novavax
Novavax, Inc. is a biotechnology company incorporated in 1987 and headquartered in Gaithersburg, Maryland, focused on discovering, developing, and commercializing vaccines to protect against serious infectious diseases. The company's proprietary technology platform combines a recombinant protein approach, nanoparticle technology, and a patented adjuvant to enhance immune response. Novavax's pipeline spans vaccine candidates targeting infectious diseases including COVID-19, influenza, respiratory syncytial virus, malaria, shingles, and other pathogens, with ongoing exploration of its adjuvant platform in oncology. The company maintains a strategic partnership with Sanofi for COVID-19 vaccine commercialization and has established licensing and collaboration agreements with major global pharmaceutical companies. Novavax trades on the NASDAQ under the ticker symbol NVAX.Explore more
Novavax Org Chart
KC
Senior VP, Policy, Government Affairs & Advoc...
KC
Global Senior VP, Regulatory Affairs
TB
Vice President & Head of Safety Operations & ...
KJ
Vice President, Assistant General Counsel
QP
Systems & Compliance Vice President, Global Q...
JS
Vice President, Chief IP Counsel
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Novavax your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Novavax has new funding data
Click to see if Novavax had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Novavax
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Novavax is spiking on competitors!
Novavax, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Novavax recently announced quarterly report
Check if Novavax has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Novavax launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Novavax
Compare insights from companies similar to Novavax, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Novavax
$413.8M
501-1,000
Public
$3.2B
1987
JJ
John JacobsPresident, CEO & Member of The Board of Directors
$97.4M
201-500
Public
$237.2M
1997
John DesjarlaisExecutive Vice President & Research & Scientific Chief & Officer
Company Profile Activity
Activity Insights
Novavax is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Novavax is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Novavax.
Novavax financials insights
Gather financial insights about Novavax, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Stock Offering
$94.6M
2014
Stock Offering
$94M
2015
Stock Offering
$201.3M
Grant
$89M
2016
Debt
$315M
2018
Stock Offering
$57.5M
2020
Multiple Rounds
$2.2B
2021
Grant
$147.3M
Novavax Tech Stack
A closer look at the technologies used by Novavax
See more technologies
Most Recent Scoops
Project
Novavax has announced that Sanofi has confirmed its intent to be among the first movers in the combination vaccine market and is in advanced discussions with regulators regarding Phase III study timing for a program using Nuvaxovid and Sanofi's flu vaccines, with Phase III initiation in either the US or EU triggering a $125 million milestone payment to Novavax.
Partnership
Novavax has partnered with Pfizer through a licensing agreement for Matrix-M, with the collaboration representing up to $500 million in potential development and commercial milestones, in addition to significant potential future royalties.
Partnership, Pharmaceuticals
Project
Novavax has announced that Sanofi is preparing a broader commercial effort for Nuvaxovid following its first full year of approval, supported by pharmacy activation and direct-to-consumer outreach, with plans to expand availability in additional international markets including the United Kingdom, Germany, and Canada.
Advertising
Earnings
Novavax has reported a net loss of $53 million for Q2 2026, ending the quarter with $743 million in cash and accounts receivable.
Earnings, Finance, Financial Operations
Earnings
Earnings, Pharmaceuticals, Finance
Novavax News & Media
Novavax Jumps 6% on Matrix-M Oncology Speculation: Is the Royalty Model the Real Story?
Retail traders are piling into Novavax on cancer-vaccine speculation, but the move that actually changed the company's business model happened quietly last week and has nothing to do with oncology.Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season
COVID-19 remains a public health challenge, particularly among older adults and high-risk populations1 Novavax's partners are ready to bring its protein-based, non-mRNA vaccine with a favorable tolerability profile to global markets, providing an important option for healthcare providers...Stocks making big moves this week: Bally's, Adobe, Novavax, Semtech, and STAAR Surgical
Check out the companies making headlines this week:NVAX Stock Alert: Biotechs Hit Post-Pandemic High on mRNA Cancer Breakthrough
NVAX stock surges amid biotech stock rally following Moderna and Merck cancer breakthrough.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Novavax
Sign Up For FreeTo access detailed company insights
Novavax, Inc. is a biotechnology company incorporated in 1987 and headquartered in Gaithersburg, Maryland, focused on discovering, developing, and commercializing vaccines to protect against serious infectious diseases. The company's proprietary technology platform combines a recombinant protein approach, nanoparticle technology, and a patented adj... Read More
